KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
Public ClinicalTrials.gov record NCT03342937. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.
Study identification
- NCT ID
- NCT03342937
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Duke University
- Other
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- Oxaliplatin+Capecitabine+Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2018
- Primary completion
- Feb 5, 2023
- Completion
- Feb 5, 2023
- Last update posted
- Mar 12, 2024
2018 – 2023
United States locations
- U.S. sites
- 7
- U.S. states
- 2
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Johnston Health Services Corporation | Clayton | North Carolina | 27520 | — |
| Duke Cancer Center, Duke University | Durham | North Carolina | 27710 | — |
| Maria Parham Healthcare Association | Henderson | North Carolina | 27536 | — |
| Scotland Health Care System | Laurinburg | North Carolina | 28352 | — |
| Southeastern Regional Medical Center | Lumberton | North Carolina | 28358 | — |
| Johnston Health Services Corporation | Smithfield | North Carolina | 27577 | — |
| Lexington Medical Center | West Columbia | South Carolina | 29169 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03342937, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2024 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03342937 live on ClinicalTrials.gov.